×
About 31,190 results
BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing
https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing1

Aug 20th, 2019 - The USPSTF recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations with an appropriate brief familial risk assessment tool. Women with a positive result on the risk assessment tool should receive genetic counseling a...

Unraveling the Safety Profile of Proton-Pump Inhibitors
https://www.jwatch.org/na49660/2019/08/19/unraveling-safety-profile-proton-pump-inhibitors
Journal Watch;

Aug 19th, 2019 - Proton-pump inhibitors (PPIs) provide important clinical benefits for many patients. However, observational studies have suggested an association between PPI use and a variety of adverse events, including dementia, osteoporosis, bone fractures, micronutrient deficiencies, pneumonia, spontaneous bacterial peritonitis, kidney disease, and enteric infections. We have observed that some patients wi...

Maintaining Full Doses of Chemotherapy Can Be Key for Breast Cancer Survival, According to New Research in JNCCN
https://www.nccn.org/about/news/newsinfo.aspx?NewsID=1641

Aug 19th, 2019 - Physicians should attempt to maintain full doses of chemotherapy, especially early in the treatment course, for intermediate or high risk breast cancer patients, according to new research published in the August 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network. The study, which looked at the impact of dose reduction with the adjuvant (post-surgery) chemotherapy combinat...

Management of Rare Ovarian Cancer Histologies
https://ascopubs.org/doi/abs/10.1200/JCO.18.02419
Gershenson, D. et. al.

Aug 11th, 2019 - Management of Rare Ovarian Cancer Histologies. David M. Gershenson, MD1. x. David M. Gershenson.

Hirsutism in Women
https://www.aafp.org/afp/2019/0801/p168.html

Jul 31st, 2019 - Hirsutism is the excessive growth of terminal hair in a typical male pattern in a female. It is often a sign of excessive androgen levels. Although many conditions can lead to hirsutism, polycystic ovary syndrome and idiopathic hyperandrogenism account for more than 85% of cases. Less common causes include idiopathic hirsutism, nonclassic congenital adrenal hyperplasia, androgen-secreting tumor...

Pulse waves measured at the wrist uncover often-missed artery changes in menopausal women
https://newsroom.heart.org/news/pulse-waves-measured-at-the-wrist-uncover-often-missed-artery-changes-in-menopausal-women

Jul 28th, 2019 - Measuring a menopausal woman’s pulse wave at her wrist can detect circulatory system changes that aren’t evident with blood pressure readings. Menopause’s effect on these radial pulse wave harmonics can help explain why women in menopause are at heightened cardiovascular disease risk.

Adnexal Torsion in Adolescents
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Adnexal-Torsion-in-Adolescents
Adnexal Torsion in Adolescents

Jul 24th, 2019 - Adnexal torsion is the fifth most common gynecologic emergency. The most common ovarian pathologies found in adolescents with adnexal torsion are benign functional ovarian cysts and benign teratomas. Torsion of malignant ovarian masses in this population is rare. In contrast to adnexal torsion in adults, adnexal torsion in pediatric and adolescent females involves an ovary without an associated...

WHO recommends dolutegravir as preferred HIV treatment option in all populations
https://www.who.int/news-room/detail/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations

Jul 21st, 2019 - Based on new evidence assessing benefits and risks, the WHO recommends the use of the HIV drug dolutegravir (DTG) as the preferred first-line and second-line treatment for all populations, including pregnant women and those of childbearing potential. Initial studies had highlighted a possible link between DTG and neural tube defects (birth defects of the brain and spinal cord that cause co...

Clinical Risk Enhances Utility of TAILORx Findings in Young Women With Breast Cancer
https://ascopost.com/issues/july-10-2019/clinical-risk-enhances-utility-of-tailorx-findings-in-young-women-with-breast-cancer/
Helwick, C. et. al.

Jul 9th, 2019 - Clinical risk factors add prognostic information that complements the 21-gene recurrence score, according to a new analysis from the landmark TAILORx trial. The integration of clinical risk with the recurrence score provides greater precision in determining recurrence risk and guiding the use of adjuvant therapy than relying solely on the recurrence score. Moreover, using all this information t...

Persistent Organic Pollutants and Breast Cancer: A Systematic Review and Critical Appraisal of the Literature
https://www.mdpi.com/2072-6694/11/8/1063
Cancers Ennour-Idrissi, K. et. al.

Jul 3rd, 2019 - Persistent organic pollutants (POPs) bioaccumulate in the food chain and have been detected in human blood and adipose tissue. Experimental studies demonstrated that POPs can cause and promote growth of breast cancer. However, inconsistent results from epidemiological studies do not support a causal relationship between POPs and breast cancer in women. To identify individual POPs that are repea...

Pfizer Receives U.S. Fda Approval For Its Oncology Biosimilar, Zirabev™ (Bevacizumab-bvzr)
https://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_u_s_fda_approval_for_its_oncology_biosimilar_zirabev_bevacizumab_bvzr

Jun 26th, 2019 - Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration(FDA) has approved ZIRABEV™ (bevacizumab-bvzr), a biosimilar to Avastin® (bevacizumab),1 for the treatment of five types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; metastatic ren...

FDA issues warnings to companies selling illegal, unapproved kratom drug products marketed for opioid cessation, pain treatment and other medical uses
https://www.fda.gov/news-events/press-announcements/fda-issues-warnings-companies-selling-illegal-unapproved-kratom-drug-products-marketed-opioid

Jun 24th, 2019 - The U.S. Food and Drug Administration issued warning letters to two marketers and distributors of kratom products – Cali Botanicals of Folsom, California, and Kratom NC of Wilmington, North Carolina – for illegally selling unapproved, misbranded kratom-containing drug products with unproven claims about their ability to treat or cure opioid addiction and withdrawal symptoms. The companies also ...

ASCO 2019 Report — Breast Cancer
https://www.jwatch.org/na49326/2019/06/19/asco-2019-report-breast-cancer
Gradishar, W. et. al.

Jun 18th, 2019 - At this year's meeting of the American Society of Clinical Oncology (ASCO 2019), held May 31 to June 4 in Chicago, investigators discussed the latest findings in cancer research. The editors of NEJM Journal Watch Oncology and Hematology were on hand to report highlights of the conference. Here, Editor-in-Chief William J. Gradishar, MD, reviews the key presentations on new breast cancer therapie...

Depression Following Acute Coronary Syndrome Events: Screening and Treatment Guidelines from the AAFP
https://www.aafp.org/afp/2019/0615/od2.html
American Family Physician;

Jun 14th, 2019 - Purpose: To review the evidence and provide clinical recommendations for the screening and treatment of depression in patients who have had a recent acute coronary syndrome event. Methods: This guideline is based on a systematic review of randomized controlled trials and observational studies from January 1, 2003, to August 15, 2017. It is an update to a previous systematic review published ...

FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
https://www.amgen.com/media/news-releases/2019/06/fda-approves-amgen-and-allergans-kanjinti-trastuzumabanns-a-biosimilar-to-herceptin-trastuzumab/

Jun 12th, 2019 - Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarc...

Testosterone - Lab Test
https://labtestsonline.org/tests/testosterone

Jun 4th, 2019 - Why Get Tested? To detect an abnormal testosterone level in males and females; in males, to help diagnose the cause of erectile dysfunction or the inability of your partner to get pregnant (infertility); in females, to help diagnose the cause of masculine physical features (virilization), infertility, or polycystic ovary syndrome (PCOS); in children, to help determine the cause of genitals tha...

Statement on warning for women of childbearing age about possible safety risks of dietary supplements containing vinpocetine
https://www.fda.gov/news-events/press-announcements/statement-warning-women-childbearing-age-about-possible-safety-risks-dietary-supplements-containing

Jun 2nd, 2019 - Today, the U.S. Food and Drug Administration is warning consumers about safety concerns regarding an ingredient called vinpocetine that is found in dietary supplements, specifically concerns about the use of this ingredient by women of childbearing age. According to data reviewed by the FDA, including a recent report by the National Institute of Health’s (NIH) National Toxicology Program (NTP),...

Antidepressants plus benzodiazepines for adults with major depression
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001026.pub2/full
The Cochrane Database of Systematic Reviews; Ogawa, Y. et. al.

Jun 2nd, 2019 - Background Anxiety frequently coexists with depression and adding benzodiazepines to antidepressant treatment is common practice to treat people with major depression. However, more evidence is needed to determine whether this combined treatment is more effective and not any more harmful than antidepressants alone. It has been suggested that benzodiazepines may lose their efficacy with long‐te...

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
https://www.nejm.org/doi/full/10.1056/NEJMoa1904819?query=recirc_curatedRelated_article
The New England Journal of Medicine; Sparano, J. et. al.

Jun 1st, 2019 - The use of adjuvant chemotherapy in patients with breast cancer may be guided by clinicopathological factors and a score based on a 21-gene assay to determine the risk of recurrence. Whether the level of clinical risk of breast cancer recurrence adds prognostic information to the recurrence score is not known. METHODS We performed a prospective trial involving 9427 women with hormone-recept...

Breast Cancer Risk Factors - breastcancer.org
https://www.breastcancer.org/risk/factors

May 31st, 2019 - Every woman wants to know what she can do to lower her risk of breast cancer. Some of the factors associated with breast cancer -- being a woman, your age, and your genetics, for example -- can't be changed. Other factors -- being overweight, lack of exercise, smoking cigarettes, and eating unhealthy food -- can be changed by making choices. By choosing the healthiest lifestyle options possible...